Pricing and market access (P&MA) is entering a new phase. While AI is becoming more embedded across the pharmaceutical industry, most P&MA organizations have only just embarked on building AI use cases often confined to isolated pilots, capturing incremental gains without changing how decisions are made or how value is created.
The question is no longer whether AI is relevant for P&MA, but how it can be applied to reshape how evidence is generated, how value is articulated, and how access strategies are designed. In P&MA specifically a strong combination of subject matter and technical expertise is crucial to build successful AI solutions. That’s why it is critical to carefully assess where to build internal solutions leveraging proprietary data and AI capabilities, and where to partner with the right vendors in a rapidly evolving AI ecosystem.
Join our upcoming webinar to explore what it takes to move toward AI-native P&MA. Drawing on our experience and industry benchmarking, our experts will share how companies can translate AI ambition into measurable impact across both internal ways of working and external evidence and value creation.
Participants will learn:
- Why AI is becoming a strategic priority for P&MA and what is driving urgency
- How leading organizations are progressing along the AI maturity curve
- Which use cases are reshaping evidence generation, launch planning, and stakeholder engagement
- Why deep P&MA and technical expertise are essential to navigating use-case opportunities and build/buy decisions
- What it means to redesign processes and operating models to be AI-enabled
- How to approach data, technology, and organizational ownership to enable scale
This webinar is free of charge. Don’t miss the opportunity to gain a practical perspective on how to embed AI into P&MA strategies and translate ambition into measurable impact.
Event details:
Thursday, June 11, 2026: 3:00 - 4:00 p.m. CEST | 9:00 - 10:00 a.m. EDT
